Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Nov 26, 2014; 2(4): 194-203
Published online Nov 26, 2014. doi: 10.13105/wjma.v2.i4.194
Systematic review and meta-analysis of Statins-Fibrates therapy in diabetic dyslipidemia patients
Shuang Zheng, Yang-Xue Li, Ting-Ting Han, Yao Zhang, Dong-Dong Jiang, Yao-Min Hu
Shuang Zheng, Yang-Xue Li, Ting-Ting Han, Yao Zhang, Dong-Dong Jiang, Yao-Min Hu, Department of Endocrinology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
Author contributions: Hu YM designed the review; Zheng S and Li YX collected the data; Han TT, Zhang Y and Jiang DD analyzed the data; Zheng S and Hu YM wrote the paper.
Supported by The National Scientific Foundation of China, No. 81270946, No. 81170758, No. 30670988
Correspondence to: Yao-Min Hu, PhD, Department of Endocrinology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, NO.160 Pujian Road, Shanghai 200127, China. amin1031@hotmail.com
Telephone: +86-21-68383447 Fax: +86-21-58394262
Received: June 6, 2014
Revised: June 24, 2014
Accepted: September 6, 2014
Published online: November 26, 2014
Processing time: 178 Days and 15.7 Hours
Core Tip

Core tip: Both dyslipidemia and type 2 diabetes were established risk factors of cardiovascular diseases. Statins therapy was highly effective at lowering low density lipoprotein cholesterol (LDL-C). However, despite the increasing use of statins as monotherapy for LDL-C reduction, a significant residual cardiovascular risk was still presented in patients with diabetic dyslipidemia. At the same time, Fenofibrate failed to alter the primary clinical endpoints significantly. How about the efficacy of statins-fibrates combination therapy in patients with diabetic dyslipidemia? The results of this meta-analysis showed the combination therapy was more effective on lipid modification and well tolerated but there was no significant effect on preventing cardiovascular diseases.